My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone (HGH)
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Deus Medical Deus Medical
SR9009 10
SR9009 10 - Deus Medical

SR9009 10 - Deus Medical

Brand:
Deus Medical
Category:
SARMs
Substance:
Stenabolic
Dosage:
10 mg/tab
Package:
50 tablets
Price:
$38.00 - $39.00
See options
Product Overview
Initially designed as a regulator of the circadian clock, SR9009 (Stenabolic) has emerged as a promising therapeutic agent for aggressive prostate cancer, specifically the PCS1 subtype. By inhibiting key genes in the LXRα/FOXM1 pathway, SR9009 disrupts cellular processes essential for tumor growth, including cell cycle progression and migration. In vitro studies reveal that SR9009 effectively reduces cell viability and enhances apoptosis without significant toxicity to normal prostate cells, highlighting its targeted anticancer potential .
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about SR9009 10 by Deus Medical, consult with your doctor or healthcare professional.

Products
Active Substances
  • Stenabolic
Common Names
  • SR9009
 About Product
Deus Medical SR9009 10mg (Stenabolic) 50 tabs
Deus Medical
International
$38.00
Active Substances
  • Stenabolic
Common Names
  • SR9009
 About Product
Deus Medical SR9009 10mg (Stenabolic) 50 tabs
Deus Medical
Europe
$38.00
Active Substances
  • Stenabolic
Common Names
  • SR9009
 About Product
SR9009 10
Deus Medical
Europe
$39.00
Show more
Explore More Products
Reviews
Leave Review
FAQ
What does Stenabolic target in prostate cancer?
Stenabolic (SR9009) targets the LXRα/FOXM1 pathway, which is key in aggressive PCS1 prostate cancer.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Does Stenabolic harm normal prostate cells?
No, Stenabolic selectively affects cancer cells and spares normal prostate tissue.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Was Stenabolic made for prostate cancer?
No, it was designed as a REV-ERB agonist but later found effective through another pathway.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.